CA
CPRX

CapWealth Advisors’s Catalyst Pharmaceutical CPRX Stock Holding History

CapWealth Advisors’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-13,000
Closed -$40K – 370
2013
Q3 		$40K Hold
13,000
– – 0.01% 163
2013
Q2 		$12K Buy
+13,000
New +$10.4K ﹤0.01% 273

Other funds holding CPRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
TCM
Tanaka Capital Management New York $59.9M AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

CapWealth Advisors's CPRX Position: Q4 2013 in Review

CapWealth Advisors sold out of Catalyst Pharmaceutical (CPRX) in Q4 2013, closing a stake of 13,000 shares — an estimated $40K sold.

CapWealth Advisors first reported a position in CPRX in Q2 2013 and held it in 2 quarters. The position peaked at $40K in Q3 2013. 32 funds tracked by Wall St. Rank hold CPRX as of Q4 2013.

  • CapWealth Advisors reported no remaining Catalyst Pharmaceutical position as of Q4 2013 after selling out during the quarter.
  • CapWealth Advisors sold 13,000 Catalyst Pharmaceutical shares in Q4 2013, an estimated $40K.
  • CapWealth Advisors first reported a position in Catalyst Pharmaceutical in Q2 2013 and held it in 2 quarters.
  • CapWealth Advisors's Catalyst Pharmaceutical position peaked at $40K in Q3 2013.
  • 32 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q4 2013.

Based on CapWealth Advisors's 13F filing for Q4 2013, filed 13 Feb 2014.